David Gerber, M.D. is a faculty member within the Hematology Oncology Division at UT Southwestern Medical Center, and Co-Director of the Phase I Laboratory Correlates Working Group.  He graduated cum laude from Yale University in New Haven, Connecticut, and his medical degree was obtained through Cornell University Medical College, New York, New York.  His internship and residency in Internal Medicine were completed at UT Southwestern Medical Center in Dallas, Texas with his fellowship in medical oncology at Johns Hopkins University School of Medicine in Baltimore, Maryland.  Dr. Gerber is board certified in Internal Medicine and Medical Oncology and holds medical licenses in both Texas and Maryland.


Dr. Gerber is genuinely interested in Lung cancer and is highly active in his research pertaining to Lung cancer, including clinical trials.  His research has generated over 100 publications that he has authored or co-authored, including articles, abstracts, book chapters, books reviews and invited manuscripts.  His studies have contributed to invitations to lecture both nationally and internationally.


Dr. Gerber not only serves on a number of committees at UT Southwestern Medical Center, but he is also an active participant for the Lung Cancer Education Committee of the American Society of Clinical Oncology (ASCO) and the Career Development Committee with the International Association for the Study of Lung Cancer (IASLC).  He serves on the editorial board of the Journal of Clinical Oncology. Dr. Gerber holds memberships to several professional societies, and has been honored with numerous awards to include Best Doctors in Dallas, D Magazine, for the last two years.


Medical School
Weill Cornell Graduate School of Medical Science (2000)
UT Southwestern Medical Center (2004), Internal Medicine
Johns Hopkins Hospital (2007), Medical Oncology

Research Interest

  • Lung cancer, clinical and translational research
  • Oncology outcomes research


Featured Publications LegendFeatured Publications

Prevalence of Autoimmune Disease Among Patients With Lung Cancer: Implications for Immunotherapy Treatment Options.
Khan SA, Pruitt SL, Xuan L, Gerber DE JAMA Oncol 2016 Jun
Phase 1 study of romidepsin plus erlotinib in advanced non-small cell lung cancer.
Gerber DE, Boothman DA, Fattah FJ, Dong Y, Zhu H, Skelton RA, Priddy LL, Vo P, Dowell JE, Sarode V, Leff R, Meek C, Xie Y, Schiller JH Lung Cancer 2015 Oct
Effect of prior cancer on outcomes in advanced lung cancer: implications for clinical trial eligibility and accrual.
Laccetti AL, Pruitt SL, Xuan L, Halm EA, Gerber DE J. Natl. Cancer Inst. 2015 Apr 107 4
Tumor-specific targeting by Bavituximab, a phosphatidylserine-targeting monoclonal antibody with vascular targeting and immune modulating properties, in lung cancer xenografts.
Gerber DE, Hao G, Watkins L, Stafford JH, Anderson J, Holbein B, Öz OK, Mathews D, Thorpe PE, Hassan G, Kumar A, Brekken RA, Sun X Am J Nucl Med Mol Imaging 2015 5 5 493-503
Impact of prior cancer on eligibility for lung cancer clinical trials.
Gerber DE, Laccetti AL, Xuan L, Halm EA, Pruitt SL J. Natl. Cancer Inst. 2014 Nov 106 11
Stromal platelet-derived growth factor receptor a (PDGFRa) provides a therapeutic target independent of tumor cell PDGFRa expression in lung cancer xenografts.
Gerber DE, Gupta P, Dellinger MT, Toombs JE, Peyton M, Duignan I, Malaby J, Bailey T, Burns C, Brekken RA, Loizos N Mol. Cancer Ther. 2012 Nov 11 11 2473-82
Consent timing and experience: modifiable factors that may influence interest in clinical research.
Gerber DE, Rasco DW, Skinner CS, Dowell JE, Yan J, Sayne JR, Xie Y J Oncol Pract 2012 Mar 8 2 91-6
How Have We Diagnosed Early-Stage Lung Cancer without Radiographic Screening? A Contemporary Single-Center Experience.
Taiwo EO, Yorio JT, Yan J, Gerber DE PLoS ONE 2012 7 12 e52313
Phase I safety and pharmacokinetic study of bavituximab, a chimeric phosphatidylserine-targeting monoclonal antibody, in patients with advanced solid tumors.
Gerber DE, Stopeck AT, Wong L, Rosen LS, Thorpe PE, Shan JS, Ibrahim NK Clin. Cancer Res. 2011 Nov 17 21 6888-96
Lung cancer diagnostic and treatment intervals in the United States: a health care disparity?
Yorio JT, Xie Y, Yan J, Gerber DE J Thorac Oncol 2009 Nov 4 11 1322-30

Professional Associations/Affiliations

  • American Society of Clinical Oncology